Le Lézard
Classified in: Health
Subject: FEA

Record date for share split in Sectra AB determined


LINKOPING, Sweden, Sept. 17, 2021 /PRNewswire/ -- The Annual General Meeting of the international medical imaging IT and cybersecurity company Sectra (STO: SECT B) on September 14, 2021, resolved to approve a share split whereby each share, regardless of class, will be split into five shares of the same class (5:1). The Board of Directors was authorized to determine the record date for the share split and has resolved that the record date will be September 27, 2021.

The share split will take place automatically via Euroclear Sweden AB and no action is required on the part of the shareholders. As a result of the share split, the total number of shares in the company will increase to 192,627,470, consisting of 13,103,460 Class A shares and 179,524,010 Class B shares.

The final day of trading in the Sectra share before the split will be September 23, 2021. The first day of trading in the Sectra share after the split will be September 24, 2021. This means that the share price from September 24, 2021, will reflect the effect of the share split. 

As a result of the split, the Sectra shares will change ISIN codes from September 24, 2021. The new ISIN codes are SE0016803233 for Class A shares and SE0016803241 for Class B shares. 

The information in this press release is such that Sectra AB (publ) is obliged to make public pursuant to Nasdaq Stockholm's Rule Book for Issuers. The information was submitted for publication, through the agency of the contact person set out below, at 8:25 a.m. CEST on September 17.

About Sectra

Sectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linköping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2020/2021 fiscal year totaled SEK 1,632 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website.

For further information, please contact:

Dr. Torbjörn Kronander, President and CEO, Sectra AB, +46 (0) 705 23 52 27

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/record-date-for-share-split-in-sectra-ab-determined,c3416669

The following files are available for download:

https://mb.cision.com/Main/1263/3416669/1469470.pdf

Record date for share split in Sectra AB determined


These press releases may also interest you

at 08:15
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 147,492...

at 08:15
PLT Health Solutions, Inc. announced that it has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient Nutricog® Cognitive Performance Complex to support cognitive...

at 08:12
The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, has published the recording of a...

at 08:10
Viridian Therapeutics, Inc. , a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m....

at 08:10
MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced the opening of two new MDVIP-affiliated practices in South Florida. Emily Salmon-Denikos, M.D., a family physician in Lake Worth,...

at 08:05
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief...



News published on and distributed by: